Journal
NATURE MEDICINE
Volume 18, Issue 3, Pages 349-351Publisher
NATURE PORTFOLIO
DOI: 10.1038/nm.2697
Keywords
-
Ask authors/readers for more resources
Kinase inhibitors are now standard treatment for patients with lung cancer whose tumors harbor specific mutant kinases. Four recent studies, including three in this issue (pages 375-384), have identified new fusion proteins involving another receptor tyrosine kinase that may potentially be responsive to existing targeted therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available